PubRank

Curt I Civin

Author PubWeight™ 52.70‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Characterization of clonogenic multiple myeloma cells. Blood 2003 5.35
2 CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A 2007 4.06
3 Mobile interspersed repeats are major structural variants in the human genome. Cell 2010 3.60
4 Hematopoietic differentiation of human embryonic stem cells progresses through sequential hematoendothelial, primitive, and definitive stages resembling human yolk sac development. Blood 2005 2.84
5 Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development 2004 2.21
6 Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther 2003 1.87
7 Kruppel-like factor 4 is essential for inflammatory monocyte differentiation in vivo. J Immunol 2008 1.83
8 Improved methods for the generation of human gene knockout and knockin cell lines. Nucleic Acids Res 2005 1.75
9 Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res 2004 1.68
10 HES1 inhibits cycling of hematopoietic progenitor cells via DNA binding. Stem Cells 2006 1.66
11 C/EBPalpha directs monocytic commitment of primary myeloid progenitors. Blood 2006 1.31
12 Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 2013 1.16
13 Targeted manipulation of mammalian genomes using designed zinc finger nucleases. Biochem Biophys Res Commun 2009 1.15
14 TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Cancer Res 2002 1.06
15 MiR-27a functions as a tumor suppressor in acute leukemia by regulating 14-3-3θ. PLoS One 2012 1.04
16 Late stage erythroid precursor production is impaired in mice with chronic inflammation. Haematologica 2012 1.02
17 Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells. Nat Med 2003 1.00
18 Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. Blood 2002 0.99
19 Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother 2011 0.98
20 Human stem-progenitor cells from neonatal cord blood have greater hematopoietic expansion capacity than those from mobilized adult blood. Exp Hematol 2002 0.95
21 TAGmapper: a web-based tool for mapping SAGE tags. Gene 2005 0.95
22 Acceleration of G(1) cooperates with core binding factor beta-smooth muscle myosin heavy chain to induce acute leukemia in mice. Cancer Res 2002 0.88
23 Translational research: toward better characterization of human embryonic stem cell lines. Stem Cells 2005 0.88
24 Deletion of tristetraprolin caused spontaneous reactive granulopoiesis by a non-cell-autonomous mechanism without disturbing long-term hematopoietic stem cell quiescence. J Immunol 2011 0.88
25 Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. J Immunol 2009 0.87
26 Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 2002 0.86
27 Human CD34+ hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. Stem Cells 2002 0.86
28 Investigation of the role of interleukin-6 and hepcidin antimicrobial peptide in the development of anemia with age. Haematologica 2013 0.85
29 Hepcidin-dependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation. Am J Hematol 2014 0.85
30 High-efficiency stable gene transduction in primary human melanocytes using a lentiviral expression system. J Invest Dermatol 2004 0.84
31 c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein. Cancer Biol Ther 2002 0.83
32 How many human embryonic stem cell lines are sufficient? A U.S. perspective. Stem Cells 2006 0.82
33 MIR144 and MIR451 regulate human erythropoiesis via RAB14. Br J Haematol 2014 0.80
34 A simple high-throughput technology enables gain-of-function screening of human microRNAs. Biotechniques 2013 0.80
35 Fas ligand as a tool for immunosuppression and generation of immune tolerance. Stem Cells 2004 0.79
36 Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: a structure-activity study. Bioorg Med Chem 2013 0.78
37 Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease. Transplantation 2006 0.78
38 Identification of miR-145 targets through an integrated omics analysis. Mol Biosyst 2014 0.77
39 Profiling tumor counterattack: do Fas ligand-containing microvesicles reduce anticancer immunity? Clin Cancer Res 2005 0.75
40 Advancing the fast-paced field of stem cell research: stem cells increases from 6 to 10 issues in its 23rd year of publication. Stem Cells 2005 0.75
41 Digital HLA allelotyping. Cancer Biol Ther 2004 0.75
42 Editorial retraction. Stem Cells 2006 0.75
43 Troublesome questions. Stem Cells 2006 0.75
44 Commitment to biomedical research: clearing unnecessary impediments to progress. Stem Cells 2002 0.75
45 Two steps forward: keeping the momentum in stem cell research. Stem Cells 2004 0.75